The FDA’s letter and warning to Alnylam (PDF) is untitled and accuses the biotech of providing open-label data that “may reasonably leave the impression that Amvuttra is more effective than it actually is.
Data from Helios-B, the phase 3 trial Alnylam conducted to evaluate the RNAi therapy, are available on a page on the website dedicated to Amvuttra’s potential to treat patients with transthyretin amyloid cardiomyopathy. The trial was a comparison of Amvuttra with a placebo. At the end of the three-year double-blind trial period, Alnylam conducted an open-label extension trial to provide all participants, including those randomized to the placebo group, with access to Amvuttra.
The website contains information from the double-blind period, as well as analyses done 6 months after the close of the double-blind period in the open-label extension. The FDA issues with the site regarding claims that are backed up by the open-label analysis, including that Amvuttra reduces the risk of death by 36% over 3.5 years compared with placebo.
Following 3.5 years, the only placebo comparator group was a group of patients who had been unblinded and given Amvuttra, the FDA stated. The open-label study design added a degree of bias and confounding to the study, and the absence of a concurrent control makes it difficult to determine what contributed to the results beyond a double-blind period, the FDA said.
The analysis wasn’t part of the original plan, and other factors may have affected the results, says Alnylam’s website. But although the FDA pointed to the cautions, it found that the open-label extension study was not capable of backing up the conclusions, so the claims still were considered misleading.
The misleading claims misbrand Amvuttra and make distributing the drug a violation of the Federal Food, Drug and Cosmetic Act, the FDA said. The agency, which sent the letter on April 23, requested that Alnylam “take immediate action” and provided it with 15 working days to respond. The website still included the claims that were disputed by the FDA as of May 7.
Alnylam has been targeted by the FDA since last year for direct-to-consumer sales and has so far received two letters but without designations. In September, the FDA sent the first letter regarding Amvuttra, as a result of a television advertisement. The advertisement implied that patients who use Amvuttra had no reason to be concerned about the side effect of cardiomyopathy, the FDA stated. But the agency stated it didn’t have trial evidence to back up that impression.
In November, the FDA closed out the first untitled letter, finding that Alnylam had responded to its concerns. The agency has issued close-out notices to all of the unearmarked letters it sent out in its early letter-sneakery campaign in early September. Letters in that series without close-out notices are letters sent to Amgen, Novartis, and UCB by the agency, among others, to Alexion.
Alnylam Pharmaceuticals has come under regulatory scrutiny after the U.S. Food and Drug Administration criticized certain efficacy claims presented on the Amvuttra website. The agency’s concerns place Alnylam in the spotlight as regulatory authorities continue closely monitoring pharmaceutical marketing practices and promotional compliance.
FDA Concerns Regarding Alnylam
According to the FDA, Alnylam allegedly presented promotional information for Amvuttra that may have overstated efficacy benefits or lacked balanced risk disclosures. The agency emphasized that pharmaceutical communications must provide accurate, evidence-based information while clearly outlining both benefits and potential risks.
The FDA’s criticism may encourage pharmaceutical companies to reassess promotional review processes and strengthen oversight of online marketing content. Biotechnology firms operating in highly competitive markets often face intense scrutiny regarding product claims and advertising practices.
The situation also highlights the increasing role of regulatory agencies in monitoring digital healthcare communication channels.
Future Outlook for Alnylam
Alnylam is expected to address the FDA’s concerns through updates to promotional materials and enhanced compliance procedures. The company will likely continue focusing on expanding Amvuttra’s commercial reach while maintaining regulatory transparency.
Future developments may also involve broader discussions within the pharmaceutical industry regarding best practices for digital drug promotion.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
